Heart Outcomes Prevention and Evaluation 4

Phase 4

Completed

• Conditions: Hypertension; Cardiovascular Disease
• Interventions: Other: Intervention; Other: Usual Care

• Registration Number: NCT01826019
• Lead Sponsor: Hamilton Health Sciences Corporation

Brief Summary

The overall objective of the HOPE-4 Phases (HT and CVD) is to develop, implement and evaluate an evidence-based, contextually appropriate programme for cardiovascular disease (CVD) risk assessment, treatment and control involving: (1) simplified algorithms implemented by non-physician health workers (NPHW) and supported by e-health technologies (tablets programmed with decision and counselling support software); (2) initiation of evidence-based cardiovascular (CV) medications and (3) treatment supporters to optimize long-term medication and lifestyle adherence.

Detailed Description

Study design: open-label, parallel cluster randomized controlled trial design.

HT Phase: Up to 30 urban and rural communities in Canada, Colombia and Malaysia will be randomized to participate in an intensive CV risk detection and control programme by NPHW or to care as usual for 12 months. NOTE: Canada will serve as a pilot study, which will be used to evaluate feasibility, time, cost and program improvements.

CVD Phase: If funded, this phase will be a continuation and expansion of HT Phase to include up to 190 urban and rural communities in countries within Asia, South America, Sub-Saharan Africa, and Canada that will be allocated to participate in an intensive CV risk detection and control programme supported by NPHWs or to care as usual for up to 6 years. NOTE: CVD Phase - currently not initiated.

Communities will be randomized 1:1 with a central randomization system to either a) intervention or b) control, after screening in the community is complete.

Study Timeline

• Study First Submitted: 2013-03-31
• Study First Submitted QC: 2013-04-05
• Study First Posted: 2013-04-08
• Study Start: 2014-08
• Status Verified: 2019-02
• Primary Completion: 2019-02
• Study Completion: 2019-02
• Last Update Submitted: 2019-02-20
• Last Update Posted: 2019-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1438

Inclusion Criteria

Individuals (≥ 50 years) with at least ONE of the following criteria:

1. SBP ≥160 mmHg in one visit
2. SBP 140-159 mmHg in one visit AND participant-reported medical diagnosis of hypertension
3. SBP 140-159 mmHg in one visit AND participant taking anti-HT medication
4. SBP ≥130 mmHg in one visit AND participant-reported medical diagnosis of diabetes
5. SBP ≥130 mmHg in one visit AND participant taking medication for diabetes
6. Participants that do not meet criteria 1-5 AND SBP 140-159 mmHg in one visit AND SBP ≥140 mmHg in a second visit ≥24 hours apart

Exclusion Criteria

1. Refusal to Consent
2. Actively involved in any study or heart health program that would compromise the protocol of HOPE-4
3. Severe co-morbid condition with life expectancy < 1 year
4. Other serious condition(s) or logistic factors likely to interfere with study participation or with the ability to complete the trial, as appropriate to country or region.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention	Intervention	Intensive CV risk detection, counselling and follow-up program by NPHW; recommended CV medications will include combinations of anti-hypertensive medications (both low and high doses) and a lipid lowering agent (e.g. statin) in accordance with treatment algorithm \[precise formulations used may differ in each country\]; use of treatment supporters to reinforce adherence.
Control - Usual Care	Usual Care	Participants in control communities will be referred to usual care.

Primary Outcome Measures

Name	Time	Method
The mean difference in change in Framingham Risk Score (FRS) between the intervention and control communities from baseline to 1 year.	Baseline to 1 year (HT phase)
Difference in major CV events [CV death, CV hospitalizations (e.g. MI, Stroke, AF, unstable or new onset angina, CHF, arterial revascularization), and end-stage renal disease] at 6 years.	Undetermined - currently not initiated and is dependent on funding (CVD Phase).

Secondary Outcome Measures

Name	Time	Method
Change in IHRS at 6 and 12 months and ChRS at 12 months	Baseline to 6 months and 12 months (HT Phase)
Number of participants receiving prescriptions for (or taking) anti-hypertensive medications (as an indication of physician adherence to treatment guidelines) at 6 and 12 months	Baseline to 6 months and 12 months (HT Phase)
Change in systolic BP (SBP) between the intervention and control communities at 6 and 12 months	Baseline to 6 months and 12 months (HT Phase)
Proportion of participants with well-controlled blood pressure at 6 and 12 months (SBP < 140 mmHg in non-diabetics and SBP < 130 mmHg in diabetics	Baseline to 6 months and 12 months (HT Phase)
Change in HDL, LDL, total cholesterol, triglycerides, and glucose levels at 12 months	Baseline to 1 year (HT Phase)
Change in smoking status at 6 and 12 months	Baseline to 6 months and 12 months (HT Phase)
Medication adherence measures at 6 and 12 months	Baseline to 6 months and 12 months (HT Phase)
Clinical events (e.g. death, CVD development, hospitalizations) at 6 and 12 months	Baseline to 6 months and 12 months (HT Phase)
Country-specific process outcomes at 6 and 12 months	Baseline to 6 months and 12 months (HT Phase)
Change in individual components of the primary outcomes in the HT Phase	Undetermined - currently not initiated and is dependent on funding (CVD Phase)
Secondary outcomes from the HT Phase	Undetermined - currently not initiated and is dependent on funding (CVD Phase)

Trial Locations

Locations (4)

Population Health Research Institute; 🇨🇦 Hamilton, Ontario, Canada

FOSCAL; 🇨🇴 Floridablanca, Santander, Colombia

UniversitiTeknologi MARA (UiTM); 🇲🇾 Sungai Buloh, Selangor, Malaysia

Simon Fraser University; 🇨🇦 Burnaby, British Columbia, Canada